Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 10/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.41 |
| ▸ | DPP4 | P27487 | 10/20 | 0.39 |
| ▸ | DPP7 | Q9UHL4 | 6/20 | 0.38 |
| ▸ | DPP8 | Q6V1X1 | 5/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | DPP9 | Q86TI2 | 3/20 | 0.38 |
| ▸ | GPR183 | P32249 | 1/20 | 0.38 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL119963 | 0.92 | GPR119 (0.41) | GPR119KCNH2DPP4DPP8DPP9 | |
| SCHEMBL122308 | 0.92 | GPR119 (0.41) | GPR119KCNH2DPP4GPR183MCHR1 | |
| SCHEMBL122282 | 0.91 | DPP4 (0.39) | KCNH2DPP4DPP7DPP8CYP2D6 | |
| SCHEMBL152098 | 0.91 | GPR119 (0.44) | GPR119KCNH2DPP4DPP7DPP8 | |
| SCHEMBL120082 | 0.90 | GPR119 (0.41) | GPR119KCNH2DPP4DPP7DPP8 | |
| SCHEMBL148585 | 0.90 | GPR119 (0.41) | GPR119KCNH2DPP4DPP7DPP8 | |
| SCHEMBL145895 | 0.90 | GPR119 (0.41) | GPR119KCNH2DPP4DPP7DPP8 | |
| SCHEMBL120073 | 0.90 | GPR119 (0.41) | GPR119KCNH2DPP4DPP7DPP8 | |
| SCHEMBL121162 | 0.89 | GPR119 (0.42) | GPR119KCNH2DPP4DPP7DPP8 | |
| SCHEMBL470613 | 0.88 | GPR119 (0.49) | GPR119KCNH2DPP4DPP7DPP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120059014-A1 | Compounds for the Treatment of Metabolic Disorders | PROSIDION LIMITED (GB) | 2012-03-08 | — | — | US | disclosed |
| US-20120059014-A1 | Compounds for the Treatment of Metabolic Disorders | PROSIDION LIMITED (GB) | 2012-03-08 | — | — | US | disclosed |
| WO-2010103334-A1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | PROSIDION LIMITED (GB) | 2010-09-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120059014-A1 | Compounds for the Treatment of Metabolic Disorders | GPR119, FFAR2, GPBAR1 | GPR119 1/4885KCNH2 2010/4885DPP4 407/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.